- Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) received ANVISA approval to manufacture and market a semaglutide injection in Brazil for adults with inadequately controlled type 2 diabetes.
- The drug will be sold in a pre‑filled, multi‑dose pen available in 2 mg/1.5 mL and 4 mg/3 mL strengths, with a commercial launch slated for the next few days in partnership with Hypera Pharma.
- Brazil’s semaglutide injectable market is estimated at ≈ USD 413 million (IQVIA, MAT June 2026), providing a sizable revenue opportunity.
- The new therapy adds to Sun Pharma’s innovative portfolio, which now accounts for about 22 % of its total sales, further diversifying its presence in Latin America.
Sun Pharma's approval to launch semaglutide in Brazil is likely to give the stock a modest boost as investors price in a new high‑growth market, though the effect may be limited to the short term.
Sign in for impact outlook, horizons, comparables, and full intelligence analysis.
Forecast from comparable, historic events. Not investment advice.
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka